Treeline Biosciences

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Treeline Biosciences sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).

3 total trials 3 currently recruiting early-phase tilt upper quartile by trial count

Treeline Biosciences: 3 sponsored US clinical trials, 3 recruiting.

Treeline Biosciences sponsors 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lymphoma, with 2 trials.

Upper-quartile sponsor footprint

Treeline Biosciences sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Treeline Biosciences pipeline

3 recruiting of 3 indexed (100% open).

Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).

Top condition: Lymphoma (2 trials), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Treeline Biosciences: open-pipeline peers nationwide

Peers matched on 3 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Treeline Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%50%100%150% Total trials Recruiting share Treeline Biosciences10xBio22nd Century GroupAA SecordAAADRS Clinical Research CenterAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Treeline Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Treeline Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

What to do with this Treeline Biosciences page

3 registered trials is a research-attention snapshot, not an endorsement of Treeline Biosciences or any single study.

  • 3 of Treeline Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Lymphoma is the condition Treeline Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lymphoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Treeline Biosciences pipeline card: 3 registered trials from official public datasets.Report a data error.